Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Editas Medicine, Inc. EDIT

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$40.5M
▲ 25.4% YoY
$-160.1M
$-165.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 40.5M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 40.5 · Net income -160.1
40M80M-100M-200M
20142017202020232025
Compound annual growth
+27.1%
−14.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −14.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−395 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -394.9% · Net -395.0%
-500%-1000%-1500%
201420192025
ROE
FY2025 · ROE -198.1%
-50%-100%-150%
201420192025
Three returns, three denominators.

Each USD of equity lost 198 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -165.8
-100M-200M
201420192025

Total assetsUSD 186.5M
EquityUSD 27.3M
CashUSD 146.6M
Gross debtUSD 58.6M
Net debtUSD -88.0M
Current ratio3.54×

The company holds more cash than debt.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
EDIT, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.10.00.00.10.00.00.00.0◌◌
Operating income $B−0.2−0.3−0.2−0.2−0.2−0.1−0.1−0.1−0.1−0.1−0.0−0.0
EBITDA $B−0.2−0.2−0.2−0.2−0.2−0.1−0.1−0.1−0.1−0.1−0.0−0.0
Income tax $B0.00.00.00.00.0◌◌◌◌◌◌◌
Net income $B−0.2−0.2−0.2−0.2−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.0
Free cash flow $B−0.2−0.2−0.1−0.2−0.2−0.2−0.0−0.1−0.0−0.1−0.0−0.0
EPS, diluted $−1.80−2.88−2.02−3.21−2.85−1.98−2.68−2.33−2.98−3.02−28.55−12.46
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %−198.1−98.1−43.2−48.2−40.6−35.4−53.6−49.5−70.2———
Shares out B0.100.080.080.070.070.060.050.050.040.040.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 46 reconciliationsAUDITED

Reconciled in 12 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Seven checks were skipped: EPS is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image